To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Daytrana (formerly known as MethyPatch) is a medicinal patch marketed by Shire Pharmaceuticals and developed under contract by Noven Pharmaceuticals. In the literature Daytrana is most commonly refered to as Methylphenidate Transdermal System (MTS).
Additional recommended knowledge
Daytrana is FDA approved as a once daily treatment of pediatric patients—ages 6 to 12—with Attention Deficit Hyperactivity Disorder.
Noven's original FDA-submission of MethylPatch indicated that it should be used for 12 hours; when the FDA rejected the submission they requested evidence that a shorter time period was safe and effective; Noven provided such evidence and Daytana was approved for the aforementioned indicated use over a 9 hour period. 
Oral-based methylphenidate pharmaceuticals are subject to first-pass hepatic metabolism and the levo-isomer is extensively metabolized, consequently contributing nothing to the dextro-isomer's clinical value; whereas MTS is transdermal, thus avoids most first-pass hepatic metabolism and the levo-isomer accounts for a thirteenth of MTS's total clinical value.
Daytrana continues this progression toward greater abuse resistance by providing a non-oral, non-granulated package that can be removed at will.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Daytrana". A list of authors is available in Wikipedia.|